Home › NDC Lookup › Drug shortages › Meperidine Hydrochloride Injection

Meperidine Hydrochloride Injection shortage

Meperidine Hydrochloride Injection is currently listed in shortage by the FDA. The FDA lists 6 affected products. This page was last refreshed from FDA data on Sep 29, 2026.

Current ⚠ Supply risk: Low Controlled substance Analgesia/Addiction 6 products 2 manufacturers 488 days · 1.3 yr First posted May 30, 2025 Updated Sep 22, 2026
Here’s the bottom line

Meperidine hydrochloride injection is currently in shortage, though all strengths — 25 mg/mL, 50 mg/mL, and 100 mg/mL — still have at least some supply available. Demerol (meperidine hydrochloride) 75 mg/mL injection is also listed by Hospira without a reported shortage.

Don’t stop or change your therapy on your own — ask your pharmacist about other manufacturers (see options) and your prescriber about a long-term plan.

Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →
6
Affected NDCs
2
Reporting manufacturers
2/2
Reporting mfrs supplying
3/3
Affected strengths supplied
0%
NDCs unavailable
488
Days in shortage
4,642
Medicaid Rx (2026)
Source: FDA Drug Shortages Database API (openFDA). Last refreshed Sep 29, 2026 · yesterday

What’s in shortage — at a glance

These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Meperidine Hydrochloride Injection. Other makers that haven’t reported a problem are shown in the green card below.

Availability of affected NDCs
From the FDA shortage report
6 NDCs
Available 6
Affected strengths still supplied
Among manufacturers reporting this shortage
3/3 strengths
Sourceable 3
FDA-reporting manufacturers with supply
Among manufacturers reporting this shortage
2/2 makers
With supply 2
✓ Other manufacturers not reporting a shortage
Still-marketed Meperidine Hydrochloride Injection from companies that have not filed an FDA shortage — these are not counted in the figures above. Stock can still vary by pharmacy.
Hospira, Inc.
Plus 9 alternative dosage forms of Meperidine Hydrochloride.
See all other options & details →
Shortage timeline
  1. Sep 22, 2026
    Currently in shortage
    6 of 6 products affected.
  2. Sep 18, 2026
    FDA refreshed this shortage record
    3 products updated.
  3. May 30, 2025
    First reported to the FDA
    6 products first listed.

Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.

What exactly is on backorder — by manufacturer

Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 3 NDCS click to expand
Status NDC / product Strength Availability Related information Reason
Current Meperidine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6052-25) NDC 00641-6052-25 — Available Additional lots are scheduled to be manufactured. Product will be made available as it is released. —
Current Meperidine Hydrochloride, Injection, 100 mg/1 mL (NDC 0641-6054-25) NDC 00641-6054-25 — Available Additional lots are scheduled to be manufactured. Product will be made available as it is released. —
Current Meperidine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-6053-25) NDC 00641-6053-25 — Available Additional lots are scheduled to be manufactured. Product will be made available as it is released. —
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 3 NDCS click to expand
Status NDC / product Strength Availability Related information Reason
Current Demerol, Injection, 50 mg/1 mL (NDC 0409-1181-30) NDC 00409-1181-30 — Available — —
Current Demerol, Injection, 50 mg/1 mL (NDC 0409-1178-30) NDC 00409-1178-30 — Available — —
Current Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30) NDC 00409-1176-30 — Available — —

These rows are manufacturer reports to the FDA for Meperidine Hydrochloride Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Meperidine Hydrochloride Injection? options further down this page.

Why is Meperidine Hydrochloride Injection in shortage?

Meperidine hydrochloride injection is currently on the FDA shortage list, though the FDA did not share a specific public reason for why the shortage exists. What we do know from the manufacturers is that products from both Hikma Pharmaceuticals and Hospira (a Pfizer company) are listed as available right now.

For Hikma's products specifically — the 25 mg/mL, 50 mg/mL, and 100 mg/mL strengths — the company has noted that additional batches are scheduled to be made at the factory, and those will be released as they're ready. Hospira's Demerol brand in the 25 mg/mL and 50 mg/mL strengths is also currently shown as available. So while there is an active shortage on record, both of these manufacturers are reporting their products as on hand, with more on the way from Hikma.

Based on the manufacturer-reported reason(s) and notes on file with the FDA for Meperidine Hydrochloride Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.

What should I do if I take Meperidine Hydrochloride Injection?

Meperidine Hydrochloride Injection is currently on the FDA shortage list, but supply overall remains fairly steady.

All three strengths — 25 mg/mL, 50 mg/mL, and 100 mg/mL — still have an available source. None of these strengths are without supply right now. That means the strength you take should still be obtainable, even though this shortage has been ongoing for over a year.

The reported reason is manufacturing timing: additional lots are scheduled to be made, and product is being released as it becomes ready. Both manufacturers on this record — Hikma and Hospira (Pfizer) — are still reporting available supply, which helps keep the shortage manageable.

Here is what I suggest:

  • Do not stop, skip, or change your dose on your own.
  • Since your strength still has supply, ask your pharmacy to order it — pharmacies can check wholesalers and both manufacturers.
  • The same medicine (Demerol) is also made by Hospira, so your pharmacy may be able to source it from another maker, though it may not be in local stock right away.
  • If your exact strength cannot be found, ask your prescriber or pharmacist about options, such as a different strength to reach your dose.

Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle these calls. This is national, manufacturer-reported information and may not match your local pharmacy's actual stock.

See “Where else can I get Meperidine Hydrochloride Injection?” below ↓ The same medicine from manufacturers not reporting a shortage, alternative dosage forms, and therapeutic equivalents with pricing.
If you are a patient:
  • Don’t stop or change the medication on your own — talk to your prescriber first.
  • If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
  • Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
  • Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
  • This is a controlled substance. Transfers between pharmacies and switching strengths have extra federal/state rules — ask the pharmacy before you assume a transfer is possible.
Keep reading
Our full Meperidine guide

Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.

Read the Meperidine guide →

Where else can I get Meperidine Hydrochloride Injection?

FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Meperidine Hydrochloride Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.

Same medicine, other manufacturers (not reported short)

Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:

ProductStrengthForm / routeManufacturerNDC
Demerol MEPERIDINE HYDROCHLORIDE 75 mg/mL Injection, Solution · Intramuscular, Intravenous, Subcutaneous Hospira, Inc. 00409-1179-30

Alternative dosage forms of Meperidine Hydrochloride

A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:

Therapeutic equivalents & pricing 6 productsclick to expand

Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.

ProductManufacturerPackageNADAC $/unitAB ratingAvailability
Meperidine Hydrochloride 25 mg/mLNDC 00641-6052-25 Hikma 25 vials — AP FDA listed
Demerol 25 mg/mLNDC 00409-1176-30 Hospira, 10 cartridges — AP FDA listed
Meperidine Hydrochloride 100 mg/mLNDC 00641-6054-25 Hikma 25 vials — AP FDA listed
Meperidine Hydrochloride 50 mg/mLNDC 00641-6053-25 Hikma 25 vials — AP FDA listed
Demerol 50 mg/mLNDC 00409-1178-30 Hospira, 10 cartridges — AP FDA listed
Demerol 50 mg/mLNDC 00409-1181-30 Hospira, 1 vial — AP FDA listed

Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.

Other drugs in the same treatment class

These are different medicines — not other versions of Meperidine Hydrochloride Injection — that fall in the same broad treatment class (opioid analgesics) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.

Identity & classification

GCN Seq No 059792
GCN 25613
HICL code 033243
Ingredient (HICL) Meperidine Hcl/Pf
HIC1 code H
Therapeutic class — broad (HIC1) Nervous System (Except Autonomic)
HIC2 code H3
Therapeutic class — intermediate (HIC2) Analgesics
HIC3 code H3A
Therapeutic class — specific (HIC3) Opioid Analgesics
AHFS code 28:08.08.00
AHFS class Opioid Agonists (28:08)
FDB label name MEPERIDINE 25 MG/ML VIAL
FDB brand name Meperidine Hcl
Legend status F — Federal legend — prescription drug or device
GPI-1465100045102010
GPI classMeperidine HCl
DEA scheduleCII
Where does this data come from?
Identity codes come from First Databank (FDB) (HICL ingredient, HIC1–3 therapeutic-class hierarchy, GCN, AHFS class, legend status) and Medi-Span GPI, mapped from a representative affected NDC. Licensed reference data — for identification only.

Other analgesia/addiction shortages

Meperidine Hydrochloride Injection shortage FAQs

Is Meperidine Hydrochloride Injection in shortage?
Yes — the FDA currently lists Meperidine Hydrochloride Injection in shortage (status: “Current”, first reported May 30, 2025). 6 of 6 products are affected. This is national, manufacturer-reported data, so your pharmacy may still have stock.
Which products are affected?
Meperidine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6052-25) (NDC 00641-6052-25); Meperidine Hydrochloride, Injection, 100 mg/1 mL (NDC 0641-6054-25) (NDC 00641-6054-25); Meperidine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-6053-25) (NDC 00641-6053-25). The full per-NDC list (availability, manufacturer and status) is in the table above — each NDC links to its own page.
When will Meperidine Hydrochloride Injection be available again?
The FDA does not publish a guaranteed restock date, and no estimated-recovery note is on file. Availability can change daily — confirm with your pharmacy.
Can I still get Meperidine Hydrochloride somewhere?
Other manufacturers (Hospira, Inc.) still market it and have not reported a shortage. 9 alternative dosage forms of Meperidine Hydrochloride are also listed. See “Where else can I get Meperidine Hydrochloride Injection?” above — stock still varies by pharmacy.
What should I do if I take Meperidine Hydrochloride Injection?
Don’t stop or change it on your own. Ask your pharmacist whether they can order it from another manufacturer or a different strength/package size, and ask your prescriber about a long-term plan before your supply runs out. Because this is a controlled substance, transfers and substitutions have extra federal/state rules — ask the pharmacy first.

Still have a question about the Meperidine Hydrochloride Injection shortage?

Ask a pharmacist about this shortage →
How to read the Supply-Risk rating
Low (1–2)Multiple manufacturers still supplying and most strengths or pack sizes sourceable.
Medium (3)Some constraint — fewer suppliers or a notable share of NDCs unavailable.
High (4–5)Down to a single source, most strengths or pack sizes unsourceable, or a long-running outage.
Where does this data come from?
Shortage records come from the FDA Drug Shortages Database API via openFDA (/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.
Data structure & sourcing designed and verified by Dr. Brian Staiger, PharmD.
← Back to all current drug shortages